We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




VEGF Aids Development of Asthma

By HospiMedica staff writers
Posted on 04 Oct 2004
Researchers have discovered that the vascular endothelial growth factor (VEGF) molecule contributes to the development of asthma, suggesting the possibility of new drugs that block VEGF receptors and signaling pathways. More...
The findings were published in the September 2004 online issue of Nature Medicine.

VEGF is normally associated with the growth of new blood vessels in the organs. In addition to this function, VEGF has been found to induce asthma-like abnormalities in the airway. When VEGF is expressed in the lungs of genetically engineered mice, asthma-like alterations develop. Prior studies showed that people with allergies and asthma have an excess of T helper type 2 cells (TH2). The researchers in the current study discovered that when VEGF is produced, the TH2 response is increased.

The researchers mimicked the increased level of VEGF found in humans with asthma by overexpressing VEGF in the lungs of mice. "To our surprise, in addition to growing new blood vessels, many other features of asthma were also seen. We saw mucous formation, airway fibrosis, and asthma-like pulmonary function abnormalities,” said principal investigator Jack A. Elias, M.D., section chief of pulmonary and critical care medicine at Yale School of Medicine (New Haven, CT, USA). They also found then when VEGF was blocked, that also blocked the asthma-like manifestations in the mouse asthma models.




Related Links:
Yale School of Medicine

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.